Akebia Corp (AKBA): רווח נקי למניה (EPS TTM)

AKBA (Akebia Therapeutics) - סמל מסחרי של החברה

Akebia Therapeutics (AKBA) leads in renal anemia therapy thanks to its drug Vafseo and protective patents. The team retains valuable regulatory experts, preventing talent attrition. The annual net income per share trend visualizes profitability, while the -0.16 metric confirms the current level. Stable demand for medications provides the company with a predictable cash flow throughout the duration of its rights.

AKBA רווח למניה ב-12 החודשים האחרונים Akebia Corp (04.07.2022 - 18.11.2026)

פילוחים אנליטיים ודוחות נתונים של חברת Akebia (AKBA)

ניתוח כל מדדי החברה:AKBA - akebia.com
סחורת הדגל של Akebia Therapeutics Inc

For Akebia Therapeutics (AKBA), the ability to monetize demand for Vafseo within the dialysis segment directly determines the efficiency of profit generation per ordinary share. By analyzing the rolling 12-month earnings per share trend, an investor assesses the net income distributed across the total equity capital, providing an objective measure of business profitability and the asset's value resilience against market risks.